Update from Lyell Immunopharma Inc (LYEL): A steady trajectory

In other words, the price has increased by $0.0000 from its previous closing price. On the day, 512000 shares were traded.

Ratios:

Our goal is to gain a better understanding of LYEL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.07 and its Current Ratio is at 16.07. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on August 28, 2023, Downgraded its rating to Neutral and sets its target price to $5 from $15 previously.

On November 14, 2022, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight and also lowered its target price recommendation from $15 to $7.

Goldman Downgraded its Buy to Neutral on November 11, 2022, whereas the target price for the stock was revised from $13 to $7.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 15 ’23 when Klausner Richard sold 58,020 shares for $2.28 per share. The transaction valued at 132,286 led to the insider holds 930,880 shares of the business.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LYEL now has a Market Capitalization of 489.14M and an Enterprise Value of 6.08M. For the stock, the TTM Price-to-Sale (P/S) ratio is 3752.86 while its Price-to-Book (P/B) ratio in mrq is 0.74. Its current Enterprise Value per Revenue stands at 46.76 whereas that against EBITDA is -0.03.

Stock Price History:

Over the past 52 weeks, LYEL has reached a high of $3.97, while it has fallen to a 52-week low of $1.32. The 50-Day Moving Average of the stock is 2.1550, while the 200-Day Moving Average is calculated to be 2.1930.

Shares Statistics:

The stock has traded on average 1.03M shares per day over the past 3-months and 976.17k shares per day over the last 10 days, according to various share statistics. A total of 253.96M shares are outstanding, with a floating share count of 116.53M. Insiders hold about 54.14% of the company’s shares, while institutions hold 27.92% stake in the company. Shares short for LYEL as of Feb 29, 2024 were 10.95M with a Short Ratio of 10.63, compared to 10.84M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.31% and a Short% of Float of 6.14%.

Earnings Estimates

Its stock is currently analyzed by 3 different market analysts. On average, analysts expect EPS of -$0.21 for the current quarter, with a high estimate of -$0.18 and a low estimate of -$0.24, while EPS last year was -$0.27. The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.18 and low estimates of -$0.25.

Analysts are recommending an EPS of between -$0.74 and -$0.97 for the fiscal current year, implying an average EPS of -$0.85. EPS for the following year is -$0.89, with 3 analysts recommending between -$0.81 and -$1.02.

Most Popular

[the_ad id="945"]